Codagenix

Codagenix making all the right moves

By GREGOERY ZELLER // A seven-figure Regional Economic Development Council award is set to push an innovative influenza vaccine toward human trials. Codagenix, a 2012 startup cofounded by Farmingdale State College biology professor J. Robert Coleman and former Stony Brook University assistant research professor Steffen Mueller, received $2.25 million through the 2015 REDC awards, which were announced in December. All told, 121 Long Island projects collected $98.3 million through the fifth-annual REDC process, many focused…


With Topspin round, Codagenix steps on the gas

By GREGORY ZELLER // Last year, when local venture firm Topspin chipped in on a $100,000 infusion for Stony Brook-based biotech Codagenix, it gave the startup a fairly clear idea of what to do with the money. “We had suggested to them that they needed to tighten up some aspects of their clinical data, and in fact they used the money to do just that,” said Steve Winick, Topspin’s managing director. “The tests came out…


Codagenix gets $100K USDA grant for Foot and Mouth vaccine

By GREGORY ZELLER // Codagenix, the Stony Brook biotech startup, has been awarded a $100,000 federal grant to develop a vaccine for the infectious Foot and Mouth Disease Virus. Funding for the project, which will be jointly run by the Plum Island Animal Disease Center, comes through the USDA’s Small Business Innovation Research program, which encourages U.S. entrepreneurs to engage in research and development with commercialization potential. While Foot and Mouth disease affects cloven-hoofed animals,…


Bioscience Park

Lights back on, finally, at Bioscience Park

Biotech firm Codagenix, a fixture at Stony Brook’s technology incubator for the past three years, is moving to the Broad Hollow Bioscience Park at SUNY Farmingdale to qualify for the state’s Start-Up NY program. (Additional reason for the move: Robert Coleman, the Codagenix COO, is an assistant professor of biology at Farmingdale.) Codagenix uses proprietary software to genetically re-code viruses, which are then synthesized from scratch as treatment candidates – one is a promising flu…